Audit: QRS - Kylo-11 for Health & Longevity of the ER frontmatter

Audit conducted on 30/08/2026 23:10 using AI4L / Grok 4.5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to a QRS card is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions bullets do not use ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Contraindications section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions bullets do not use ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Key Interactions section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Protocol section lists more than three distinct actionable aspects; all three QRS action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides at least three time-to-effect aspects; all three QRS time sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information; the section is present.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢

Issues 30/08/2026 23:10

Pass rate 100.00%. No issues found.

Issues 30/08/2026 23:01

1. 7.4 — Specialist at-a-glance phrasing: At-a-glance (QRS line 433) uses “investigator-assigned drug-related unwanted effects”. “investigator-assigned” is a specialist causality-classification term a non-specialist would not use unprompted or know exactly.

Fixes 30/08/2026 23:04

1. 7.4 — Specialist at-a-glance phrasing: Replaced “investigator-assigned drug-related unwanted effects” with “drug-related unwanted effects” in at-a-glance so the summary uses plain language.

Issues 30/08/2026 22:45

1. 1.2 / 1.3 — Safety phrasing strengthened: At-a-glance (line 433) changes the ER Conclusion’s “no investigator-assigned drug-related unwanted effects” to “no unwanted effects from the drug”, dropping the investigator-assigned qualifier and strengthening the safety claim.

Fixes 30/08/2026 22:45

1. 1.2 / 1.3 — Safety phrasing restored: Replaced at-a-glance “no unwanted effects from the drug” with the ER Conclusion phrasing “no investigator-assigned drug-related unwanted effects”.

Issues 30/08/2026 22:39

1. 1.1 / 1.3 — Time to effect 48 weeks: time_1_value is “48 weeks” under the Time to effect label. The ER Practical Considerations section says published 48-week figures describe durability after the fall, not an overnight change, and that the nadir is after about 1–2 months.

Fixes 30/08/2026 22:39

1. 1.1 / 1.3 — Time to effect 48 weeks: Moved the 1–2 month nadir into time_1_value and recast the former “48 weeks” cell as “48-week durability”, matching the ER’s durability-after-the-fall wording instead of time-to-onset.

Issues 30/08/2026 22:14

1. 7.4 — Specialist particle name: at_a_glance uses “lipoprotein(a)”, a specialist biochemical name a non-specialist would not use unprompted, instead of the plain-language gloss already in the same sentence.

2. 12.3 — Mechanistic healthspan clause: Speculative benefits retain “Longer healthspan from a lower lifetime Lp(a) burden”, a mechanistic “from…” explanation, rather than the key fact “Longer healthspan”.

Fixes 30/08/2026 22:14

1. 7.4 — Specialist particle name: Removed “lipoprotein(a)” from at_a_glance, leaving the plain-language gloss “a genetically set particle tied to artery disease and aortic valve thickening”.

2. 12.3 — Mechanistic healthspan clause: Shortened the speculative benefit from “Longer healthspan from a lower lifetime Lp(a) burden” to “Longer healthspan”.

Issues 30/08/2026 22:08

1. 7.4 — Specialist phrasing in at-a-glance: At-a-glance (line 433) uses “investigator-assigned drug-related unwanted effects”; a non-specialist would not use “investigator-assigned” unprompted.

Fixes 30/08/2026 22:08

1. 7.4 — Specialist phrasing in at-a-glance: Replaced “investigator-assigned drug-related unwanted effects” with “no unwanted effects from the drug”, dropping “otherwise” to keep the summary at 60 words.

Issues 30/08/2026 21:56

1. 1.2 / 1.3 — Dropped cautious safety phrasing: At-a-glance (QRS line 433) changes the ER Conclusion’s “no investigator-assigned drug-related unwanted effects” in “otherwise healthy young adults” to “no drug-related unwanted effects” in “healthy young adults”, dropping the cautious qualifiers.

Fixes 30/08/2026 21:56

1. 1.2 / 1.3 — Dropped cautious safety phrasing: Restored ER Conclusion phrasing in at-a-glance: “healthy young adults” → “otherwise healthy young adults” and “no drug-related unwanted effects” → “no investigator-assigned drug-related unwanted effects”, dropping the word “dose” to stay at 60 words.

Issues 30/08/2026 21:33

1. 2.7 — Unnecessary medical jargon: Protocol time-to-effect subtext uses unexplained specialist terms (LPA siRNAs and nadir at lines 499–500; GalNAc-siRNAs and RISC at lines 507–511). Monitoring Why cells keep “knockdown” (line 608) and “Hepatocyte GalNAc delivery” (line 641). Qualitative Assessment uses “induration” without the ER’s plain-language gloss “a firm bump under the skin” (line 713).

Fixes 30/08/2026 21:33

1. 2.7 — Unnecessary medical jargon: Replaced unexplained specialist terms in time-to-effect subtext (LPA siRNAs/nadir → lipoprotein(a) gene-silencing drugs/lowest point; GalNAc-siRNAs/RISC → liver-targeted RNA drugs/liver effect), rewrote Monitoring Why cells in plain language (knockdown → lowering; Hepatocyte GalNAc delivery → liver-cell delivery of the drug), and restored the ER gloss “a firm bump under the skin” on induration.

Issues 30/08/2026 21:26

1. 4.2 / 4.3 — Invented time labels: Time-to-effect cells use invented labels “Durability” (line 483) and “Nadir” (line 494) instead of ER bold labels. The ER has Time to effect: (Practical Considerations) and Half-life versus effect: (Protocol), not Durability: or Nadir:.
2. 7.4 — Specialist clinical phrasing: At-a-glance (line 433) uses specialist clinical-register phrasing “investigator-assigned drug-related unwanted effects”; a non-specialist would not use “investigator-assigned” unprompted.

Fixes 30/08/2026 21:26

1. 4.2 / 4.3 — Invented time labels: Replaced invented cell labels “Durability” and “Nadir” with the ER bold label “Time to effect”.
2. 7.4 — Specialist clinical phrasing: Replaced “investigator-assigned drug-related unwanted effects” in at-a-glance with “drug-related unwanted effects”.

Issues 30/08/2026 21:13

1. 1.1 / 11.4 — Half-life value unsupported: time_3_value (QRS line 508) states “About 48 hours in plasma” as the half-life figure. ER Protocol (line 241) says a numerical human half-life for Kylo-11 is unpublished and only that class GalNAc-siRNAs leave plasma within about 48 hours.
2. 1.2 / 1.3 — Cautious phrasing dropped: at_a_glance (QRS line 433) drops the ER Conclusion’s “investigator-assigned” qualifier (ER line 321), strengthening “no investigator-assigned drug-related unwanted effects” to “no drug-related unwanted effects”, and broadens “artery disease and aortic valve thickening” to “artery and valve disease”. The same pair also covers presenting an unpublished half-life as a 48-hour value.
3. 2.5 / 2.6 / 2.9 — Imperative monitoring cadence: monitoring_cadence (QRS line 704) uses “Draw at 4 weeks…”, converting the ER’s informational “A practical cadence is a draw at 4 weeks…” (ER line 286) into an instruction that addresses the reader.

Fixes 30/08/2026 21:13

1. 1.1 / 11.4 — Half-life value unsupported: Changed time_3_value from “About 48 hours in plasma” to “Unpublished for Kylo-11” and appended “a numerical human half-life is unpublished” to time_3_sub, matching ER Protocol wording.
2. 1.2 / 1.3 — Cautious phrasing dropped: Restored the ER Conclusion’s “investigator-assigned” qualifier and “artery disease and aortic valve thickening” in at_a_glance, replacing the strengthened “no drug-related unwanted effects” and broadened “artery and valve disease”.
3. 2.5 / 2.6 / 2.9 — Imperative monitoring cadence: Changed monitoring_cadence from “Draw at 4 weeks…” to “A draw at 4 weeks…”, matching the ER’s informational phrasing instead of an instruction to the reader.

Issues 30/08/2026 20:57

1. 1.3 — Softened study qualifiers: At-a-glance (line 433) drops ER Conclusion qualifiers: “healthy young adults” becomes “healthy adults”, and “a single dose at 225 mg or higher” becomes “One dose”, softening who was studied and at what dose year-long suppression was shown.
2. 7.4 — Specialist trial phrasing: At-a-glance (line 433) uses “investigator-assigned” in “investigator-assigned drug-related unwanted effects”; a non-specialist would not use that clinical-trial term unprompted or know its exact meaning.

Fixes 30/08/2026 20:57

1. 1.3 / 7.4 — At-a-glance qualifiers and jargon: Restored ER Conclusion qualifiers in at-a-glance (“healthy young adults”; “A 225 mg or higher dose”) and replaced “investigator-assigned drug-related unwanted effects” with plain-language “drug-related unwanted effects”.